StockData
CG Oncology, Inc. logo

CG Oncology, Inc. (CGON) stock

CGONNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30
$78.94−5.84 (-6.89%)

Close on Nov 17, 2026Market cap $7.00BP/E –Yield –

CG Oncology operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

CG Oncology's operating income for the twelve months ending Sep 30, 2026 was -$264.74M. For fiscal 2025 it was -$190.77M.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$190.77M–
FY2024Dec 31, 2024-$114.67M–
FY2023Dec 31, 2023-$55.45M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$63.25M–
Q2 FY2026Jun 30, 2026-$86.40M–
Q1 FY2026Mar 31, 2026-$66.39M–
Q4 FY2025Dec 31, 2025-$48.70M–
Q3 FY2025Sep 30, 2025-$51.13M–
Q2 FY2025Jun 30, 2025-$48.74M–
Q1 FY2025Mar 31, 2025-$42.20M–
Q4 FY2024Dec 31, 2024-$38.05M–
Q3 FY2024Sep 30, 2024-$28.30M–
Q2 FY2024Jun 30, 2024-$25.85M–
Q1 FY2024Mar 31, 2024-$22.47M–
Q4 FY2023Dec 31, 2023-$19.36M–
Q3 FY2023Sep 30, 2023-$14.04M–
Q2 FY2023Jun 30, 2023-$12.33M–
Q1 FY2023Mar 31, 2023-$9.72M–

More CG Oncology figures

See a number that looks wrong?